Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Recommendations
Nevro price target raised to $145 from $135 at Morgan Stanley » 08:31
06/18/20
06/18
08:31
06/18/20
08:31
NVRO

Nevro

$124.15 /

-1.5 (-1.19%)

Morgan Stanley analyst…

Morgan Stanley analyst David Lewis raised the firm's price target on Nevro to $145 from $135 based on his forecasts for non-surgical refractory back pain, or NSRBP. NSRBP patients potentially represent up to 30% of all Nevro patients in the U.S. and Lewis notes that while COVID-19 slowed the progress of the last few patients remaining in the SENZA-NSRBP study treatment arm to receive implants, they are expected to be completed by the end of this month. Lewis, who projects total NSRBP revenue can double to $200M by 2025 from about $100M in 2019, keeps an Overweight rating on Nevro shares.

ShowHide Related Items >><<
NVRO Nevro
$124.15 /

-1.5 (-1.19%)

NVRO Nevro
$124.15 /

-1.5 (-1.19%)

06/08/20 UBS
Nevro upgraded to Neutral from Sell at UBS
05/06/20 Citi
Nevro price target raised to $137 from $130 at Citi
04/02/20 SunTrust
Nevro price target lowered to $120 from $146 at SunTrust
04/02/20 Wells Fargo
Nevro price target lowered to $126 from $158 at Wells Fargo
NVRO Nevro
$124.15 /

-1.5 (-1.19%)

NVRO Nevro
$124.15 /

-1.5 (-1.19%)

Upgrade
Nevro upgraded to Neutral from Sell at UBS » 06:14
06/08/20
06/08
06:14
06/08/20
06:14
NVRO

Nevro

$127.00 /

+5.56 (+4.58%)

UBS analyst Matthew…

UBS analyst Matthew Taylor upgraded Nevro to Neutral from Sell with a price target of $132, up from $100. The analyst cites his more positive view on the company's underlying fundamentals, its execution potential, and its "competitive positioning". Taylor further notes that Nevro has shown positive traction with Omnia and has also seen early signs of recovery with 30% of backlog patients rescheduled, adding that neuro implants should be in the first group of procedures to come back given the severity of illness and a quick, profitable outpatient procedure.

ShowHide Related Items >><<
NVRO Nevro
$127.00 /

+5.56 (+4.58%)

NVRO Nevro
$127.00 /

+5.56 (+4.58%)

05/06/20 Citi
Nevro price target raised to $137 from $130 at Citi
04/02/20 SunTrust
Nevro price target lowered to $120 from $146 at SunTrust
04/02/20 Wells Fargo
Nevro price target lowered to $126 from $158 at Wells Fargo
03/04/20 Citi
Nevro initiated with a Buy at Citi
NVRO Nevro
$127.00 /

+5.56 (+4.58%)

NVRO Nevro
$127.00 /

+5.56 (+4.58%)

Hot Stocks
Nevro appoints Roderick MacLeod as CFO » 07:02
06/04/20
06/04
07:02
06/04/20
07:02
NVRO

Nevro

$127.41 /

-1.71 (-1.32%)

Nevro appointed Roderick…

Nevro appointed Roderick MacLeod as CFO, effective June 15, with global responsibility for Finance, IT and Customer Service. MacLeod succeeds Andrew Galligan, who is retiring but will remain with the company during a transition period. MacLeod recently he served as Vice President of Finance of Stryker Endoscopy, a $1.8B division of Stryker Corp that develops and manufactures medical devices used in minimally invasive surgical procedures.

ShowHide Related Items >><<
NVRO Nevro
$127.41 /

-1.71 (-1.32%)

NVRO Nevro
$127.41 /

-1.71 (-1.32%)

05/06/20 Citi
Nevro price target raised to $137 from $130 at Citi
04/02/20 SunTrust
Nevro price target lowered to $120 from $146 at SunTrust
04/02/20 Wells Fargo
Nevro price target lowered to $126 from $158 at Wells Fargo
03/04/20 Citi
Nevro initiated with a Buy at Citi
NVRO Nevro
$127.41 /

-1.71 (-1.32%)

NVRO Nevro
$127.41 /

-1.71 (-1.32%)

Over a month ago
Conference/Events
UBS to hold a virtual conference » 04:55
05/20/20
05/20
04:55
05/20/20
04:55
RDHL

RedHill Biopharma

$7.19 /

+0.28 (+4.05%)

, ANGO

AngioDynamics

$11.05 /

+0.11 (+1.01%)

, CDXS

Codexis

$11.15 /

-0.42 (-3.63%)

, AHCO

AdaptHealth

$16.68 /

+0.18 (+1.09%)

, APLT

Applied Therapeutics

$47.53 /

+2.41 (+5.34%)

, TFX

Teleflex

$346.33 /

-6.665 (-1.89%)

, UHS

Universal Health

$101.01 /

+0.55 (+0.55%)

, HRC

Hill-Rom

$98.94 /

-2.17 (-2.15%)

, NVRO

Nevro

$122.31 /

+0.47 (+0.39%)

, AMED

Amedisys

$190.01 /

-2.98 (-1.54%)

, ESTA

Establishment Labs

$16.25 /

-0.86 (-5.03%)

, HUM

Humana

$395.51 /

+4.41 (+1.13%)

, VKTX

Viking Therapeutics

$7.05 /

-0.09 (-1.26%)

, WST

West Pharmaceutical

$211.46 /

-7.14 (-3.27%)

Global Healthcare Virtual…

Global Healthcare Virtual Conference will be held on May 18-20.

ShowHide Related Items >><<
WST West Pharmaceutical
$211.46 /

-7.14 (-3.27%)

VKTX Viking Therapeutics
$7.05 /

-0.09 (-1.26%)

UHS Universal Health
$101.01 /

+0.55 (+0.55%)

TFX Teleflex
$346.33 /

-6.665 (-1.89%)

RDHL RedHill Biopharma
$7.19 /

+0.28 (+4.05%)

NVRO Nevro
$122.31 /

+0.47 (+0.39%)

HUM Humana
$395.51 /

+4.41 (+1.13%)

HRC Hill-Rom
$98.94 /

-2.17 (-2.15%)

ESTA Establishment Labs
$16.25 /

-0.86 (-5.03%)

CDXS Codexis
$11.15 /

-0.42 (-3.63%)

APLT Applied Therapeutics
$47.53 /

+2.41 (+5.34%)

ANGO AngioDynamics
$11.05 /

+0.11 (+1.01%)

AMED Amedisys
$190.01 /

-2.98 (-1.54%)

AHCO AdaptHealth
$16.68 /

+0.18 (+1.09%)

RDHL RedHill Biopharma
$7.19 /

+0.28 (+4.05%)

02/27/20 Roth Capital
RedHill Biopharma price target lowered to $15 from $20.25 at Roth Capital
07/12/19 WBB Securities
RedHill Biopharma upgraded to Strong Buy from Buy at WBB Securities
ANGO AngioDynamics
$11.05 /

+0.11 (+1.01%)

04/08/20
Fly Intel: Top five analyst downgrades
04/08/20 KeyBanc
AngioDynamics downgraded to Sector Weight from Overweight at KeyBanc
04/07/20 KeyBanc
AngioDynamics downgraded to Sector Weight from Overweight at KeyBanc
12/30/19 Stifel
Avanos makes 'welcome addition' with 'highly experienced' CFO, says Stifel
CDXS Codexis
$11.15 /

-0.42 (-3.63%)

03/10/20 Benchmark
Codexis initiated with a Buy at Benchmark
AHCO AdaptHealth
$16.68 /

+0.18 (+1.09%)

02/28/20 Deutsche Bank
AdaptHealth price target raised to $19 from $12 at Deutsche Bank
01/31/20
Fly Intel: Top five analyst initiations
01/30/20 Stifel
AdaptHealth initiated with a Buy at Stifel
01/07/20 Jefferies
Jefferies starts AdaptHealth at Buy with $15 price target
APLT Applied Therapeutics
$47.53 /

+2.41 (+5.34%)

04/22/20
Fly Intel: Top five analyst initiations
04/22/20 Goldman Sachs
Applied Therapeutics initiated with a Buy at Goldman Sachs
02/27/20 Barclays
Applied Therapeutics initiated with an Overweight at Barclays
02/27/20 Barclays
Applied Therapeutics initiated with an Overweight at Barclays
TFX Teleflex
$346.33 /

-6.665 (-1.89%)

05/01/20 Piper Sandler
Teleflex price target lowered to $375 from $425 at Piper Sandler
04/03/20 Raymond James
Teleflex price target lowered to $360 from $450 at Raymond James
02/20/20 Piper Sandler
Teleflex price target raised to $425 from $400 at Piper Sandler
12/12/19 Wells Fargo
SeaSpine, Glaukos double-downgraded to Underweight at Wells Fargo
UHS Universal Health
$101.01 /

+0.55 (+0.55%)

04/29/20 Deutsche Bank
Universal Health price target lowered to $135 from $165 at Deutsche Bank
04/28/20 Citi
Universal Health price target lowered to $128 from $157 at Citi
03/26/20 JPMorgan
Channel checks suggest hospital total revenues down 40%-60%, says JPMorgan
03/23/20 BofA
Universal Health downgraded to Neutral on Vegas recession risk at BofA
HRC Hill-Rom
$98.94 /

-2.17 (-2.15%)

03/17/20 Barclays
Hill-Rom upgraded to Overweight from Equal Weight at Barclays
12/17/19 Morgan Stanley
Hill-Rom upgraded to Overweight on accelerating momentum at Morgan Stanley
12/17/19 Morgan Stanley
Hill-Rom upgraded to Overweight from Equal Weight at Morgan Stanley
06/27/19 Raymond James
Hill-Rom's DoD contract win a 'nice development,' says Raymond James
NVRO Nevro
$122.31 /

+0.47 (+0.39%)

05/06/20 Citi
Nevro price target raised to $137 from $130 at Citi
04/02/20 SunTrust
Nevro price target lowered to $120 from $146 at SunTrust
04/02/20 Wells Fargo
Nevro price target lowered to $126 from $158 at Wells Fargo
03/04/20 Citi
Nevro initiated with a Buy at Citi
AMED Amedisys
$190.01 /

-2.98 (-1.54%)

05/11/20 Raymond James
Amedisys price target lowered to $210 from $225 at Raymond James
05/07/20 Benchmark
Amedisys downgraded to Hold on limited near-term visibility at Benchmark
05/07/20 Benchmark
Amedisys downgraded to Hold from Buy at Benchmark
03/09/20 Benchmark
Benchmark upgrades Amedisys to Buy on Home Health boost from crowded hospitals
ESTA Establishment Labs
$16.25 /

-0.86 (-5.03%)

05/14/20
Fly Intel: Top five analyst initiations
05/14/20 Goldman Sachs
Establishment Labs initiated with a Neutral at Goldman Sachs
01/03/20 BTIG
Zimmer Biomet, Staar Surgical, ViewRay among top 2020 picks at BTIG
07/24/19 Wells Fargo
Allergan recall to benefit Establishment and Sientra, says Wells Fargo
HUM Humana
$395.51 /

+4.41 (+1.13%)

05/04/20 Mizuho
Humana price target raised to $420 from $405 at Mizuho
04/30/20 Credit Suisse
Humana price target raised to $423 from $400 at Credit Suisse
04/30/20 Oppenheimer
Humana price target raised to $425 from $400 at Oppenheimer
04/29/20 Cantor Fitzgerald
Humana comments on telephonic sales 'positive' for eHealth, says Cantor
VKTX Viking Therapeutics
$7.05 /

-0.09 (-1.26%)

05/05/20 Chardan
Viking Therapeutics initiated with a Buy at Chardan
05/04/20 B. Riley FBR
Viking Therapeutics price target lowered to $12 from $16 at B. Riley FBR
05/01/20 BTIG
Viking Therapeutics initiated with a Buy at BTIG
02/27/20 H.C. Wainwright
Viking Therapeutics price target lowered to $18 from $31 at H.C. Wainwright
WST West Pharmaceutical
$211.46 /

-7.14 (-3.27%)

04/24/20 BofA
West Pharmaceutical upgraded to Neutral from Underperform at BofA
04/24/20 BofA
West Pharmaceutical upgraded to Neutral from Underperform at BofA
12/12/19
Fly Intel: Top five analyst downgrades
12/12/19 BofA
West Pharmaceutical downgraded to Underperform from Neutral at BofA/Merrill
WST West Pharmaceutical
$211.46 /

-7.14 (-3.27%)

VKTX Viking Therapeutics
$7.05 /

-0.09 (-1.26%)

UHS Universal Health
$101.01 /

+0.55 (+0.55%)

TFX Teleflex
$346.33 /

-6.665 (-1.89%)

RDHL RedHill Biopharma
$7.19 /

+0.28 (+4.05%)

NVRO Nevro
$122.31 /

+0.47 (+0.39%)

HUM Humana
$395.51 /

+4.41 (+1.13%)

HRC Hill-Rom
$98.94 /

-2.17 (-2.15%)

ESTA Establishment Labs
$16.25 /

-0.86 (-5.03%)

CDXS Codexis
$11.15 /

-0.42 (-3.63%)

APLT Applied Therapeutics
$47.53 /

+2.41 (+5.34%)

ANGO AngioDynamics
$11.05 /

+0.11 (+1.01%)

AMED Amedisys
$190.01 /

-2.98 (-1.54%)

AHCO AdaptHealth
$16.68 /

+0.18 (+1.09%)

UHS Universal Health
$101.01 /

+0.55 (+0.55%)

HUM Humana
$395.51 /

+4.41 (+1.13%)

VKTX Viking Therapeutics
$7.05 /

-0.09 (-1.26%)

UHS Universal Health
$101.01 /

+0.55 (+0.55%)

NVRO Nevro
$122.31 /

+0.47 (+0.39%)

HUM Humana
$395.51 /

+4.41 (+1.13%)

APLT Applied Therapeutics
$47.53 /

+2.41 (+5.34%)

ANGO AngioDynamics
$11.05 /

+0.11 (+1.01%)

VKTX Viking Therapeutics
$7.05 /

-0.09 (-1.26%)

HUM Humana
$395.51 /

+4.41 (+1.13%)

Conference/Events
UBS to hold a virtual conference » 04:55
05/19/20
05/19
04:55
05/19/20
04:55
RDHL

RedHill Biopharma

$6.91 /

+0.18 (+2.67%)

, ANGO

AngioDynamics

$10.94 /

+0.93 (+9.29%)

, CDXS

Codexis

$11.57 /

+0.47 (+4.23%)

, AHCO

AdaptHealth

$16.50 /

+0.21 (+1.29%)

, APLT

Applied Therapeutics

$45.12 /

+1.22 (+2.78%)

, TFX

Teleflex

$353.00 /

+18.395 (+5.50%)

, UHS

Universal Health

$100.46 /

+7.86 (+8.49%)

, HRC

Hill-Rom

$101.11 /

+1.3 (+1.30%)

, NVRO

Nevro

$121.84 /

+4.09 (+3.47%)

, AMED

Amedisys

$192.99 /

+8.12 (+4.39%)

, ESTA

Establishment Labs

$17.11 /

+0.71 (+4.33%)

, HUM

Humana

$391.10 /

-7.25 (-1.82%)

, VKTX

Viking Therapeutics

$7.14 /

+0.04 (+0.56%)

, WST

West Pharmaceutical

$218.60 /

+4.73 (+2.21%)

Global Healthcare Virtual…

Global Healthcare Virtual Conference will be held on May 18-20.

ShowHide Related Items >><<
WST West Pharmaceutical
$218.60 /

+4.73 (+2.21%)

VKTX Viking Therapeutics
$7.14 /

+0.04 (+0.56%)

UHS Universal Health
$100.46 /

+7.86 (+8.49%)

TFX Teleflex
$353.00 /

+18.395 (+5.50%)

RDHL RedHill Biopharma
$6.91 /

+0.18 (+2.67%)

NVRO Nevro
$121.84 /

+4.09 (+3.47%)

HUM Humana
$391.10 /

-7.25 (-1.82%)

HRC Hill-Rom
$101.11 /

+1.3 (+1.30%)

ESTA Establishment Labs
$17.11 /

+0.71 (+4.33%)

CDXS Codexis
$11.57 /

+0.47 (+4.23%)

APLT Applied Therapeutics
$45.12 /

+1.22 (+2.78%)

ANGO AngioDynamics
$10.94 /

+0.93 (+9.29%)

AMED Amedisys
$192.99 /

+8.12 (+4.39%)

AHCO AdaptHealth
$16.50 /

+0.21 (+1.29%)

RDHL RedHill Biopharma
$6.91 /

+0.18 (+2.67%)

02/27/20 Roth Capital
RedHill Biopharma price target lowered to $15 from $20.25 at Roth Capital
07/12/19 WBB Securities
RedHill Biopharma upgraded to Strong Buy from Buy at WBB Securities
ANGO AngioDynamics
$10.94 /

+0.93 (+9.29%)

04/08/20
Fly Intel: Top five analyst downgrades
04/08/20 KeyBanc
AngioDynamics downgraded to Sector Weight from Overweight at KeyBanc
04/07/20 KeyBanc
AngioDynamics downgraded to Sector Weight from Overweight at KeyBanc
12/30/19 Stifel
Avanos makes 'welcome addition' with 'highly experienced' CFO, says Stifel
CDXS Codexis
$11.57 /

+0.47 (+4.23%)

03/10/20 Benchmark
Codexis initiated with a Buy at Benchmark
AHCO AdaptHealth
$16.50 /

+0.21 (+1.29%)

02/28/20 Deutsche Bank
AdaptHealth price target raised to $19 from $12 at Deutsche Bank
01/31/20
Fly Intel: Top five analyst initiations
01/30/20 Stifel
AdaptHealth initiated with a Buy at Stifel
01/07/20 Jefferies
Jefferies starts AdaptHealth at Buy with $15 price target
APLT Applied Therapeutics
$45.12 /

+1.22 (+2.78%)

04/22/20
Fly Intel: Top five analyst initiations
04/22/20 Goldman Sachs
Applied Therapeutics initiated with a Buy at Goldman Sachs
02/27/20 Barclays
Applied Therapeutics initiated with an Overweight at Barclays
02/27/20 Barclays
Applied Therapeutics initiated with an Overweight at Barclays
TFX Teleflex
$353.00 /

+18.395 (+5.50%)

05/01/20 Piper Sandler
Teleflex price target lowered to $375 from $425 at Piper Sandler
04/03/20 Raymond James
Teleflex price target lowered to $360 from $450 at Raymond James
02/20/20 Piper Sandler
Teleflex price target raised to $425 from $400 at Piper Sandler
12/12/19 Wells Fargo
SeaSpine, Glaukos double-downgraded to Underweight at Wells Fargo
UHS Universal Health
$100.46 /

+7.86 (+8.49%)

04/29/20 Deutsche Bank
Universal Health price target lowered to $135 from $165 at Deutsche Bank
04/28/20 Citi
Universal Health price target lowered to $128 from $157 at Citi
03/26/20 JPMorgan
Channel checks suggest hospital total revenues down 40%-60%, says JPMorgan
03/23/20 BofA
Universal Health downgraded to Neutral on Vegas recession risk at BofA
HRC Hill-Rom
$101.11 /

+1.3 (+1.30%)

03/17/20 Barclays
Hill-Rom upgraded to Overweight from Equal Weight at Barclays
12/17/19 Morgan Stanley
Hill-Rom upgraded to Overweight on accelerating momentum at Morgan Stanley
12/17/19 Morgan Stanley
Hill-Rom upgraded to Overweight from Equal Weight at Morgan Stanley
06/27/19 Raymond James
Hill-Rom's DoD contract win a 'nice development,' says Raymond James
NVRO Nevro
$121.84 /

+4.09 (+3.47%)

05/06/20 Citi
Nevro price target raised to $137 from $130 at Citi
04/02/20 SunTrust
Nevro price target lowered to $120 from $146 at SunTrust
04/02/20 Wells Fargo
Nevro price target lowered to $126 from $158 at Wells Fargo
03/04/20 Citi
Nevro initiated with a Buy at Citi
AMED Amedisys
$192.99 /

+8.12 (+4.39%)

05/11/20 Raymond James
Amedisys price target lowered to $210 from $225 at Raymond James
05/07/20 Benchmark
Amedisys downgraded to Hold on limited near-term visibility at Benchmark
05/07/20 Benchmark
Amedisys downgraded to Hold from Buy at Benchmark
03/09/20 Benchmark
Benchmark upgrades Amedisys to Buy on Home Health boost from crowded hospitals
ESTA Establishment Labs
$17.11 /

+0.71 (+4.33%)

05/14/20
Fly Intel: Top five analyst initiations
05/14/20 Goldman Sachs
Establishment Labs initiated with a Neutral at Goldman Sachs
01/03/20 BTIG
Zimmer Biomet, Staar Surgical, ViewRay among top 2020 picks at BTIG
07/24/19 Wells Fargo
Allergan recall to benefit Establishment and Sientra, says Wells Fargo
HUM Humana
$391.10 /

-7.25 (-1.82%)

05/04/20 Mizuho
Humana price target raised to $420 from $405 at Mizuho
04/30/20 Credit Suisse
Humana price target raised to $423 from $400 at Credit Suisse
04/30/20 Oppenheimer
Humana price target raised to $425 from $400 at Oppenheimer
04/29/20 Cantor Fitzgerald
Humana comments on telephonic sales 'positive' for eHealth, says Cantor
VKTX Viking Therapeutics
$7.14 /

+0.04 (+0.56%)

05/05/20 Chardan
Viking Therapeutics initiated with a Buy at Chardan
05/04/20 B. Riley FBR
Viking Therapeutics price target lowered to $12 from $16 at B. Riley FBR
05/01/20 BTIG
Viking Therapeutics initiated with a Buy at BTIG
02/27/20 H.C. Wainwright
Viking Therapeutics price target lowered to $18 from $31 at H.C. Wainwright
WST West Pharmaceutical
$218.60 /

+4.73 (+2.21%)

04/24/20 BofA
West Pharmaceutical upgraded to Neutral from Underperform at BofA
04/24/20 BofA
West Pharmaceutical upgraded to Neutral from Underperform at BofA
12/12/19
Fly Intel: Top five analyst downgrades
12/12/19 BofA
West Pharmaceutical downgraded to Underperform from Neutral at BofA/Merrill
WST West Pharmaceutical
$218.60 /

+4.73 (+2.21%)

VKTX Viking Therapeutics
$7.14 /

+0.04 (+0.56%)

UHS Universal Health
$100.46 /

+7.86 (+8.49%)

TFX Teleflex
$353.00 /

+18.395 (+5.50%)

RDHL RedHill Biopharma
$6.91 /

+0.18 (+2.67%)

NVRO Nevro
$121.84 /

+4.09 (+3.47%)

HUM Humana
$391.10 /

-7.25 (-1.82%)

HRC Hill-Rom
$101.11 /

+1.3 (+1.30%)

ESTA Establishment Labs
$17.11 /

+0.71 (+4.33%)

CDXS Codexis
$11.57 /

+0.47 (+4.23%)

APLT Applied Therapeutics
$45.12 /

+1.22 (+2.78%)

ANGO AngioDynamics
$10.94 /

+0.93 (+9.29%)

AMED Amedisys
$192.99 /

+8.12 (+4.39%)

AHCO AdaptHealth
$16.50 /

+0.21 (+1.29%)

UHS Universal Health
$100.46 /

+7.86 (+8.49%)

HUM Humana
$391.10 /

-7.25 (-1.82%)

VKTX Viking Therapeutics
$7.14 /

+0.04 (+0.56%)

UHS Universal Health
$100.46 /

+7.86 (+8.49%)

NVRO Nevro
$121.84 /

+4.09 (+3.47%)

HUM Humana
$391.10 /

-7.25 (-1.82%)

APLT Applied Therapeutics
$45.12 /

+1.22 (+2.78%)

ANGO AngioDynamics
$10.94 /

+0.93 (+9.29%)

VKTX Viking Therapeutics
$7.14 /

+0.04 (+0.56%)

HUM Humana
$391.10 /

-7.25 (-1.82%)

Conference/Events
UBS to hold a virtual conference » 08:53
05/18/20
05/18
08:53
05/18/20
08:53
RDHL

RedHill Biopharma

$6.73 /

-0.11 (-1.61%)

, ANGO

AngioDynamics

$10.01 /

+0.01 (+0.10%)

, CDXS

Codexis

$11.10 /

+0.35 (+3.26%)

, AHCO

AdaptHealth

$16.29 /

-0.11 (-0.67%)

, APLT

Applied Therapeutics

$43.90 /

+0.85 (+1.97%)

, TFX

Teleflex

$334.60 /

+1.41 (+0.42%)

, UHS

Universal Health

$92.60 /

+1.13 (+1.24%)

, HRC

Hill-Rom

$99.81 /

+0.4 (+0.40%)

, NVRO

Nevro

$117.75 /

-2.27 (-1.89%)

, AMED

Amedisys

$184.87 /

+7.66 (+4.32%)

, ESTA

Establishment Labs

$16.40 /

-0.91 (-5.26%)

, HUM

Humana

$398.35 /

+12.43 (+3.22%)

, VKTX

Viking Therapeutics

$7.10 /

+0.2 (+2.90%)

, WST

West Pharmaceutical

$213.87 /

+3.45 (+1.64%)

Global Healthcare Virtual…

Global Healthcare Virtual Conference will be held on May 18-20.

ShowHide Related Items >><<
WST West Pharmaceutical
$213.87 /

+3.45 (+1.64%)

VKTX Viking Therapeutics
$7.10 /

+0.2 (+2.90%)

UHS Universal Health
$92.60 /

+1.13 (+1.24%)

TFX Teleflex
$334.60 /

+1.41 (+0.42%)

RDHL RedHill Biopharma
$6.73 /

-0.11 (-1.61%)

NVRO Nevro
$117.75 /

-2.27 (-1.89%)

HUM Humana
$398.35 /

+12.43 (+3.22%)

HRC Hill-Rom
$99.81 /

+0.4 (+0.40%)

ESTA Establishment Labs
$16.40 /

-0.91 (-5.26%)

CDXS Codexis
$11.10 /

+0.35 (+3.26%)

APLT Applied Therapeutics
$43.90 /

+0.85 (+1.97%)

ANGO AngioDynamics
$10.01 /

+0.01 (+0.10%)

AMED Amedisys
$184.87 /

+7.66 (+4.32%)

AHCO AdaptHealth
$16.29 /

-0.11 (-0.67%)

RDHL RedHill Biopharma
$6.73 /

-0.11 (-1.61%)

02/27/20 Roth Capital
RedHill Biopharma price target lowered to $15 from $20.25 at Roth Capital
07/12/19 WBB Securities
RedHill Biopharma upgraded to Strong Buy from Buy at WBB Securities
ANGO AngioDynamics
$10.01 /

+0.01 (+0.10%)

04/08/20
Fly Intel: Top five analyst downgrades
04/08/20 KeyBanc
AngioDynamics downgraded to Sector Weight from Overweight at KeyBanc
04/07/20 KeyBanc
AngioDynamics downgraded to Sector Weight from Overweight at KeyBanc
12/30/19 Stifel
Avanos makes 'welcome addition' with 'highly experienced' CFO, says Stifel
CDXS Codexis
$11.10 /

+0.35 (+3.26%)

03/10/20 Benchmark
Codexis initiated with a Buy at Benchmark
AHCO AdaptHealth
$16.29 /

-0.11 (-0.67%)

02/28/20 Deutsche Bank
AdaptHealth price target raised to $19 from $12 at Deutsche Bank
01/31/20
Fly Intel: Top five analyst initiations
01/30/20 Stifel
AdaptHealth initiated with a Buy at Stifel
01/07/20 Jefferies
Jefferies starts AdaptHealth at Buy with $15 price target
APLT Applied Therapeutics
$43.90 /

+0.85 (+1.97%)

04/22/20
Fly Intel: Top five analyst initiations
04/22/20 Goldman Sachs
Applied Therapeutics initiated with a Buy at Goldman Sachs
02/27/20 Barclays
Applied Therapeutics initiated with an Overweight at Barclays
02/27/20 Barclays
Applied Therapeutics initiated with an Overweight at Barclays
TFX Teleflex
$334.60 /

+1.41 (+0.42%)

05/01/20 Piper Sandler
Teleflex price target lowered to $375 from $425 at Piper Sandler
04/03/20 Raymond James
Teleflex price target lowered to $360 from $450 at Raymond James
02/20/20 Piper Sandler
Teleflex price target raised to $425 from $400 at Piper Sandler
12/12/19 Wells Fargo
SeaSpine, Glaukos double-downgraded to Underweight at Wells Fargo
UHS Universal Health
$92.60 /

+1.13 (+1.24%)

04/29/20 Deutsche Bank
Universal Health price target lowered to $135 from $165 at Deutsche Bank
04/28/20 Citi
Universal Health price target lowered to $128 from $157 at Citi
03/26/20 JPMorgan
Channel checks suggest hospital total revenues down 40%-60%, says JPMorgan
03/23/20 BofA
Universal Health downgraded to Neutral on Vegas recession risk at BofA
HRC Hill-Rom
$99.81 /

+0.4 (+0.40%)

03/17/20 Barclays
Hill-Rom upgraded to Overweight from Equal Weight at Barclays
12/17/19 Morgan Stanley
Hill-Rom upgraded to Overweight on accelerating momentum at Morgan Stanley
12/17/19 Morgan Stanley
Hill-Rom upgraded to Overweight from Equal Weight at Morgan Stanley
06/27/19 Raymond James
Hill-Rom's DoD contract win a 'nice development,' says Raymond James
NVRO Nevro
$117.75 /

-2.27 (-1.89%)

05/06/20 Citi
Nevro price target raised to $137 from $130 at Citi
04/02/20 SunTrust
Nevro price target lowered to $120 from $146 at SunTrust
04/02/20 Wells Fargo
Nevro price target lowered to $126 from $158 at Wells Fargo
03/04/20 Citi
Nevro initiated with a Buy at Citi
AMED Amedisys
$184.87 /

+7.66 (+4.32%)

05/11/20 Raymond James
Amedisys price target lowered to $210 from $225 at Raymond James
05/07/20 Benchmark
Amedisys downgraded to Hold on limited near-term visibility at Benchmark
05/07/20 Benchmark
Amedisys downgraded to Hold from Buy at Benchmark
03/09/20 Benchmark
Benchmark upgrades Amedisys to Buy on Home Health boost from crowded hospitals
ESTA Establishment Labs
$16.40 /

-0.91 (-5.26%)

05/14/20
Fly Intel: Top five analyst initiations
05/14/20 Goldman Sachs
Establishment Labs initiated with a Neutral at Goldman Sachs
01/03/20 BTIG
Zimmer Biomet, Staar Surgical, ViewRay among top 2020 picks at BTIG
07/24/19 Wells Fargo
Allergan recall to benefit Establishment and Sientra, says Wells Fargo
HUM Humana
$398.35 /

+12.43 (+3.22%)

05/04/20 Mizuho
Humana price target raised to $420 from $405 at Mizuho
04/30/20 Credit Suisse
Humana price target raised to $423 from $400 at Credit Suisse
04/30/20 Oppenheimer
Humana price target raised to $425 from $400 at Oppenheimer
04/29/20 Cantor Fitzgerald
Humana comments on telephonic sales 'positive' for eHealth, says Cantor
VKTX Viking Therapeutics
$7.10 /

+0.2 (+2.90%)

05/05/20 Chardan
Viking Therapeutics initiated with a Buy at Chardan
05/04/20 B. Riley FBR
Viking Therapeutics price target lowered to $12 from $16 at B. Riley FBR
05/01/20 BTIG
Viking Therapeutics initiated with a Buy at BTIG
02/27/20 H.C. Wainwright
Viking Therapeutics price target lowered to $18 from $31 at H.C. Wainwright
WST West Pharmaceutical
$213.87 /

+3.45 (+1.64%)

04/24/20 BofA
West Pharmaceutical upgraded to Neutral from Underperform at BofA
04/24/20 BofA
West Pharmaceutical upgraded to Neutral from Underperform at BofA
12/12/19
Fly Intel: Top five analyst downgrades
12/12/19 BofA
West Pharmaceutical downgraded to Underperform from Neutral at BofA/Merrill
WST West Pharmaceutical
$213.87 /

+3.45 (+1.64%)

VKTX Viking Therapeutics
$7.10 /

+0.2 (+2.90%)

UHS Universal Health
$92.60 /

+1.13 (+1.24%)

TFX Teleflex
$334.60 /

+1.41 (+0.42%)

RDHL RedHill Biopharma
$6.73 /

-0.11 (-1.61%)

NVRO Nevro
$117.75 /

-2.27 (-1.89%)

HUM Humana
$398.35 /

+12.43 (+3.22%)

HRC Hill-Rom
$99.81 /

+0.4 (+0.40%)

ESTA Establishment Labs
$16.40 /

-0.91 (-5.26%)

CDXS Codexis
$11.10 /

+0.35 (+3.26%)

APLT Applied Therapeutics
$43.90 /

+0.85 (+1.97%)

ANGO AngioDynamics
$10.01 /

+0.01 (+0.10%)

AMED Amedisys
$184.87 /

+7.66 (+4.32%)

AHCO AdaptHealth
$16.29 /

-0.11 (-0.67%)

UHS Universal Health
$92.60 /

+1.13 (+1.24%)

HUM Humana
$398.35 /

+12.43 (+3.22%)

VKTX Viking Therapeutics
$7.10 /

+0.2 (+2.90%)

UHS Universal Health
$92.60 /

+1.13 (+1.24%)

NVRO Nevro
$117.75 /

-2.27 (-1.89%)

HUM Humana
$398.35 /

+12.43 (+3.22%)

APLT Applied Therapeutics
$43.90 /

+0.85 (+1.97%)

ANGO AngioDynamics
$10.01 /

+0.01 (+0.10%)

AMED Amedisys
$184.87 /

+7.66 (+4.32%)

VKTX Viking Therapeutics
$7.10 /

+0.2 (+2.90%)

HUM Humana
$398.35 /

+12.43 (+3.22%)

Hot Stocks
Nevro announces CE mark approval for the Senza Omnia SCS system » 07:14
05/14/20
05/14
07:14
05/14/20
07:14
NVRO

Nevro

$117.65 /

-1.34 (-1.13%)

Nevro announced it has…

Nevro announced it has received CE mark approval for the Senza Omnia Spinal Cord Stimulation system. "Following a successful launch in the United States late last year, we are excited to now have approval for the Senza Omnia SCS system in Europe," said D. Keith Grossman, Chairman, CEO and President of Nevro.

ShowHide Related Items >><<
NVRO Nevro
$117.65 /

-1.34 (-1.13%)

NVRO Nevro
$117.65 /

-1.34 (-1.13%)

05/06/20 Citi
Nevro price target raised to $137 from $130 at Citi
04/02/20 SunTrust
Nevro price target lowered to $120 from $146 at SunTrust
04/02/20 Wells Fargo
Nevro price target lowered to $126 from $158 at Wells Fargo
03/04/20 Citi
Nevro initiated with a Buy at Citi
NVRO Nevro
$117.65 /

-1.34 (-1.13%)

NVRO Nevro
$117.65 /

-1.34 (-1.13%)

Recommendations
Nevro price target raised to $137 from $130 at Citi » 06:26
05/06/20
05/06
06:26
05/06/20
06:26
NVRO

Nevro

$118.48 /

+7.18 (+6.45%)

Citi analyst Joanne…

Citi analyst Joanne Wuensch raised the firm's price target on Nevro to $137 from $130 and reiterates a Buy rating on the shares following the company's Q1 results.

ShowHide Related Items >><<
NVRO Nevro
$118.48 /

+7.18 (+6.45%)

04/02/20 SunTrust
Nevro price target lowered to $120 from $146 at SunTrust
04/02/20 Wells Fargo
Nevro price target lowered to $126 from $158 at Wells Fargo
03/04/20 Citi
Nevro initiated with a Buy at Citi
02/26/20 SVB Leerink
Nevro price target raised to $158 from $146 at SVB Leerink
Hot Stocks
Nevro withdraws previously announced FY20 guidance » 16:42
05/05/20
05/05
16:42
05/05/20
16:42
NVRO

Nevro

$118.48 /

+7.18 (+6.45%)

Due to the rapidly…

Due to the rapidly evolving environment and continued uncertainties resulting from the impact of COVID-19, Nevro withdrew its previously announced annual guidance for 2020 on April 1. Due to the uncertain scope and duration of the pandemic, and the timing of global economic recovery, the Company cannot, at this time, reliably estimate the future impact on its operations and financial results.

ShowHide Related Items >><<
NVRO Nevro
$118.48 /

+7.18 (+6.45%)

04/02/20 SunTrust
Nevro price target lowered to $120 from $146 at SunTrust
04/02/20 Wells Fargo
Nevro price target lowered to $126 from $158 at Wells Fargo
03/04/20 Citi
Nevro initiated with a Buy at Citi
02/26/20 SVB Leerink
Nevro price target raised to $158 from $146 at SVB Leerink
Earnings
Nevro reports Q1 EPS (78c), consensus (97c) » 16:42
05/05/20
05/05
16:42
05/05/20
16:42
NVRO

Nevro

$118.48 /

+7.18 (+6.45%)

Reports Q1 revenue…

Reports Q1 revenue $87.5M, consensus $89.46M. "Through February, Nevro's performance was trending above our expectations with U.S. trials and permanent implants growing at 20% and 29%, respectively, over the prior year. We experienced a significant decline in both trials and permanent implants of our products in March with the impact of the COVID-19 pandemic," said D. Keith Grossman, Chairman, CEO and President of Nevro. "Our highest priority now is to support the health and safety of our customers, patients and employees. We continue to support our customers as they prepare for the return of procedural volumes, in accordance with public health and safety guidelines, to help the growing number of patients who suffer from chronic debilitating pain."

ShowHide Related Items >><<
NVRO Nevro
$118.48 /

+7.18 (+6.45%)

04/02/20 SunTrust
Nevro price target lowered to $120 from $146 at SunTrust
04/02/20 Wells Fargo
Nevro price target lowered to $126 from $158 at Wells Fargo
03/04/20 Citi
Nevro initiated with a Buy at Citi
02/26/20 SVB Leerink
Nevro price target raised to $158 from $146 at SVB Leerink

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.